[go: up one dir, main page]

SK7352001A3 - Substituted indolealkanoic acids compounds and use thereof for reducing serum triglyceride levels - Google Patents

Substituted indolealkanoic acids compounds and use thereof for reducing serum triglyceride levels Download PDF

Info

Publication number
SK7352001A3
SK7352001A3 SK735-2001A SK7352001A SK7352001A3 SK 7352001 A3 SK7352001 A3 SK 7352001A3 SK 7352001 A SK7352001 A SK 7352001A SK 7352001 A3 SK7352001 A3 SK 7352001A3
Authority
SK
Slovakia
Prior art keywords
group
alkyl
optionally substituted
phenyl
alkoxy
Prior art date
Application number
SK735-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Janet Sredy
Jorge Jacot
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of SK7352001A3 publication Critical patent/SK7352001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SK735-2001A 1998-12-01 1999-12-01 Substituted indolealkanoic acids compounds and use thereof for reducing serum triglyceride levels SK7352001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11039598P 1998-12-01 1998-12-01
PCT/US1999/028483 WO2000032180A2 (fr) 1998-12-01 1999-12-01 Techniques permettant de reduire les taux de glucose serique et de triglycerides et d'inhiber l'angiogenese a l'aide d'acides indolealcanoiques substitues

Publications (1)

Publication Number Publication Date
SK7352001A3 true SK7352001A3 (en) 2002-06-04

Family

ID=22332786

Family Applications (1)

Application Number Title Priority Date Filing Date
SK735-2001A SK7352001A3 (en) 1998-12-01 1999-12-01 Substituted indolealkanoic acids compounds and use thereof for reducing serum triglyceride levels

Country Status (30)

Country Link
US (5) US6555568B1 (fr)
EP (1) EP1135124B1 (fr)
JP (1) JP2002531398A (fr)
KR (1) KR20010086075A (fr)
CN (1) CN1368883A (fr)
AP (1) AP2001002146A0 (fr)
AT (1) ATE265210T1 (fr)
AU (1) AU770925B2 (fr)
BG (1) BG105531A (fr)
BR (1) BR9915882A (fr)
CA (1) CA2385845A1 (fr)
CZ (1) CZ20011864A3 (fr)
DE (1) DE69916881T2 (fr)
DZ (1) DZ2953A1 (fr)
EE (1) EE200100296A (fr)
HK (1) HK1046372A1 (fr)
HU (1) HUP0104953A3 (fr)
ID (1) ID30037A (fr)
IL (1) IL143247A0 (fr)
MX (1) MXPA02003118A (fr)
NO (1) NO20012690L (fr)
OA (1) OA12035A (fr)
PL (1) PL349016A1 (fr)
SK (1) SK7352001A3 (fr)
TN (1) TNSN99224A1 (fr)
TR (1) TR200101539T2 (fr)
TW (1) TW584560B (fr)
WO (1) WO2000032180A2 (fr)
YU (1) YU40101A (fr)
ZA (1) ZA200104126B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK7522001A3 (en) * 1998-03-31 2002-02-05 Inst For Pharm Discovery Inc Substituted indolealkanoic acids
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
US6521659B2 (en) 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
AU2001259668A1 (en) * 2000-05-09 2001-11-20 The Institute For Pharmaceutical Discovery Llc Methods for testing compounds useful for treating diabetic complications
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2003000253A1 (fr) 2001-06-20 2003-01-03 Wyeth Derives d'acide indole substitue utilises en tant qu'inhibiteurs de l'inhibiteur-1 (pai-1) de l'activateur plasminogene
AU2003297787A1 (en) 2002-12-10 2004-06-30 Wyeth Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
MXPA05006282A (es) 2002-12-10 2005-08-19 Wyeth Corp Derivados del acido 1h-indol-1-il acetico de 3-alquilo y 3-arilalquilo sustituido como inhibidores del inhibidor-1 de activador de plasminogeno (pai-1).
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
ATE411288T1 (de) 2002-12-10 2008-10-15 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
MXPA05006287A (es) 2002-12-10 2005-09-08 Wyeth Corp Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
US7592361B2 (en) 2003-04-28 2009-09-22 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
RU2007106868A (ru) 2004-08-23 2008-09-27 Вайет (Us) Оксазол-нафтиловые кислоты и их применение в качестве модуляторов ингибитора активатора плазминогена-1 (pai) для лечения тромбоза и сердечно-сосудистых заболеваний
BRPI0514549A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de pirrol-naftila como inibidores de pai-1
WO2006023866A2 (fr) 2004-08-23 2006-03-02 Wyeth Acides thiazolo-naphthyliques
US20060135540A1 (en) * 2004-11-30 2006-06-22 Jack Lin PPAR active compounds
AU2005311925A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR PPAR active compounds
CA2617372A1 (fr) 2005-08-17 2007-02-22 Wyeth Indoles substitues et procedes d'utilisation de ceux-ci
RU2419618C2 (ru) * 2005-09-07 2011-05-27 Плекссикон, Инк. Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
EP2046740B1 (fr) 2006-07-22 2012-05-23 Oxagen Limited Composés présentant une activité d'antagonistes crth2
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
HRP20140045T1 (hr) 2008-01-18 2014-02-14 Atopix Therapeutics Limited Spojevi koji imaju antagonistiäśku aktivnost na crth2
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093026A1 (fr) 2008-01-22 2009-07-30 Oxagen Limited Composés présentant une activité antagoniste du récepteur crth2
WO2009093029A1 (fr) 2008-01-22 2009-07-30 Oxagen Limited Composés présentant une activité antagoniste de crth2
EP3563842A1 (fr) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) * 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
DE3684410D1 (de) 1985-11-07 1992-04-23 Pfizer Heterocyclische oxophthalazinylessigsaeure.
US4960785A (en) * 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
WO1993012786A1 (fr) 1986-07-10 1993-07-08 Howard Harry R Jr Derives d'indolinone
US4868301A (en) 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
WO1991009019A1 (fr) 1989-12-15 1991-06-27 Pfizer Inc. Acides acetiques d'oxophtalazinyle substitues et analogues de ceux-ci
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5236945A (en) 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
JP3195455B2 (ja) 1993-01-06 2001-08-06 ウェルファイド株式会社 キノリン−３−酢酸誘導体、その製造法と用途
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
AU7634694A (en) 1993-08-20 1995-03-21 University Of Medicine And Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
JPH09165371A (ja) * 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
SK7522001A3 (en) 1998-03-31 2002-02-05 Inst For Pharm Discovery Inc Substituted indolealkanoic acids
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
US20120065203A1 (en) 2012-03-15
WO2000032180A3 (fr) 2000-11-16
TW584560B (en) 2004-04-21
DE69916881T2 (de) 2005-02-03
US20060074114A1 (en) 2006-04-06
YU40101A (sh) 2005-07-19
US6964980B2 (en) 2005-11-15
BG105531A (en) 2001-12-31
CN1368883A (zh) 2002-09-11
CA2385845A1 (fr) 2000-06-08
NO20012690L (no) 2001-07-27
CZ20011864A3 (cs) 2002-03-13
BR9915882A (pt) 2001-08-21
DZ2953A1 (fr) 2004-03-15
WO2000032180A2 (fr) 2000-06-08
NO20012690D0 (no) 2001-05-31
HK1046372A1 (zh) 2003-01-10
AU2161600A (en) 2000-06-19
OA12035A (en) 2006-05-02
PL349016A1 (en) 2002-06-17
AU770925B2 (en) 2004-03-11
ID30037A (id) 2001-11-01
EE200100296A (et) 2003-02-17
ZA200104126B (en) 2002-05-21
TR200101539T2 (tr) 2001-12-21
US20030216452A1 (en) 2003-11-20
TNSN99224A1 (fr) 2005-11-10
ATE265210T1 (de) 2004-05-15
AP2001002146A0 (en) 2001-06-30
US6555568B1 (en) 2003-04-29
JP2002531398A (ja) 2002-09-24
DE69916881D1 (de) 2004-06-03
IL143247A0 (en) 2002-04-21
EP1135124A2 (fr) 2001-09-26
EP1135124B1 (fr) 2004-04-28
US20100324105A1 (en) 2010-12-23
HUP0104953A2 (hu) 2002-07-29
MXPA02003118A (es) 2004-04-21
KR20010086075A (ko) 2001-09-07
HUP0104953A3 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
SK7352001A3 (en) Substituted indolealkanoic acids compounds and use thereof for reducing serum triglyceride levels
JP3494990B2 (ja) 置換されたインドールアルカノール酸
US6521659B2 (en) Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20010044437A1 (en) Methods for reducing uric acid levels